Pliant Therapeutics (PLRX) Fundamentals 2026 — Revenue Analysis | SniperIQ
Pliant Therapeutics (PLRX) is a US-listed Healthcare company in Biotechnology with a market capitalization of $66M, trading at
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Pliant Therapeutics's market cap?
Pliant Therapeutics (PLRX) has a market capitalization of approximately $66M, trading at
What is Pliant Therapeutics's P/E ratio?
Pliant Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Pliant Therapeutics?
Pliant Therapeutics runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Pliant Therapeutics pay a dividend?
Pliant Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Pliant Therapeutics financially healthy?
Pliant Therapeutics carries a debt-to-equity ratio of 0.17x and a current ratio of 16.89x, with a market beta of 1.22. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Pliant Therapeutics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Pliant Therapeutics (PLRX) the key facts are: market cap $66M, 52-week range 1.055-1.95. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Pliant Therapeutics's full fundamentals live
Get Pliant Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.